Features | Partner Sites | Information | LinkXpress
Sign In
Advantech Europe

New Injection Device Approved for Methotrexate

By HospiMedica International staff writers
Posted on 31 Oct 2013
Image: The Otrexup self-injector in 10 mg formulation (Photo courtesy of Antares Pharma).
Image: The Otrexup self-injector in 10 mg formulation (Photo courtesy of Antares Pharma).
A self-injection device for the subcutaneous administration of methotrexate (MTX) facilitates drug delivery for arthritis sufferers.

The Otrexup self-injector is intended for use by adults with active, severe rheumatoid arthritis (RA) or psoriasis who have not responded to or been able to tolerate first line therapy, as well as for children with active polyarticular juvenile idiopathic arthritis. The device is not indicated for use in children with psoriasis, nor should it be used by pregnant women. And while MTX is also used in the treatment of cancer, Otrexup is not indicated for that use.

Methotrexate is considered a disease-modifying antirheumatic drug (DMARD), effective in relieving joint inflammation and pain, slowing disease progression, and preventing disability by delaying joint destruction. People with RA may be more likely to continue treatment with MTX than with other DMARDs, with more than 50% of people who take MTX for RA continuing to take the medicine for more than three years, longer than any other DMARD. The Otrexup self-injector is a product of Antares Pharma (Ewing, NJ, USA), and has been approved by the US Food and Drug Administration (FDA).

“We are very pleased to receive approval from the FDA for Otrexup because we believe it is an important step up in the standard of care for people living with rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and psoriasis,” said Paul Wotton, PhD, president and CEO of Antares Pharma.

“The availability of an easy and safe way to administer subcutaneous methotrexate may overcome some of the current barriers to parenteral administration, which could enable more patients to realize the possibility of continued disease control and therefore benefit from subcutaneous methotrexate,” commented Michael Schiff, MD, of the University of Colorado (Denver, USA).

MTX is a cornerstone of therapy for RA and psoriasis, usually given orally once a week, but a substantial number of patients do not respond adequately or cannot tolerate the side effects of the drug, such as nausea, abdominal pain, and dyspepsia. Those patients can be given methotrexate with subcutaneous injections, which can increase the drug's bioavailability, but injection can also pose problems for patients who are afraid of needles or do not have enough manual dexterity remaining to manage needles, syringes, and vials.

Related Links:

Antares Pharma

Asian Healthcare Show
Cincinnati Sub-Zero


Surgical Techniques

view channel
Image: The Cardioband direct annuloplasty system (Photo courtesy of Valtech Cardio).

Annuloplasty System Promotes Mitral Valve Repair

An implantable mitral reconstruction device proves a highly effective treatment option for reducing functional mitral regurgitation (MR). The Cardioband mitral reconstruction system combines a reconstruction... Read more

Women's Health

view channel

Pregnancy Complications Raise Heart Disease Risk

A new study suggests a high correlation between women who experienced complications during pregnancy and those facing death from heart disease later in life. Researchers at the Public Health Institute (PHI; Oakland, CA, USA; Berkeley, CA) conducted a study involving 14,062 women, examining pregnancy events over five... Read more

Patient Care

view channel
Image: The NIFTY cup (Photo courtesy of PATH).

NIFTY Cup Aids Infants Who Cannot Breastfeed

A novel cup has been designed to facilitate feeding and prevent starvation in infants in developing countries who are unable to breastfeed. The Neonatal Intuitive Feeding TechnologY (NIFTY) cup, developed... Read more

Hospital News

view channel

Universal Health Services to Acquire Foundations Recovery Network

Hospital operator Universal Health Services (UHS; King of Prussia, PA, USA) has entered an agreement to buy addiction treatment provider Foundations Recovery Network (FRN; Brentwood, TN, USA) for USD 350 million. Founded in 1995, FRN is a leader in addiction treatment and focused on treating adults with addiction and... Read more


view channel

Qualcomm Buys Connectivity Company Capsule Technologie

Qualcomm Life (San Diego, CA, USA) has purchased Capsule Technologie (Andover, MA, USA) in a bid to become one of the world's largest open connected health ecosystems. Financial details remain undisclosed. Qualcomm Life, a division of the 3G, 4G, and next-generation wireless technology conglomerate Qualcomm (San Diego,... Read more


08 Oct 2015 - 10 Oct 2015
08 Oct 2015 - 10 Oct 2015
08 Oct 2015 - 10 Oct 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.